Search results for "Ús terapèutic"

showing 9 items of 9 documents

Extra virgin olive oil consumption reduces the risk of osteoporotic fractures in the PREDIMED trial.

2018

BACKGROUND & AIMS: The incidence of osteoporotic fractures is lower in countries in the Mediterranean basin. Virgin olive oil, a key component of the Mediterranean Diet (MDiet), with recognised beneficial effects on metabolism and cardiovascular health, may decrease the risk of osteoporotic fractures. The aim to this study was to explore the effect of chronic consumption of total olive oil and its varieties on the risk of osteoporosis-related fractures in a middle-aged and elderly Mediterranean population. METHODS: We included all participants (n = 870) recruited in the Reus (Spain) centre of the PREvención con DIeta MEDiterránea (PREDIMED) trial. Individuals, aged 55-80 years at high cardi…

0301 basic medicineMalemedicine.medical_specialtyAgingMediterranean dietPopulationOsteoporotic fractures030209 endocrinology & metabolismCritical Care and Intensive Care MedicineLower riskDiet MediterraneanMediterrània (Regió)03 medical and health sciences0302 clinical medicineEnvironmental healthmedicineHumanseducationOlive OilAgededucation.field_of_study030109 nutrition & dieteticsNutrition and Dietetics:Ciencias de la Salud::Salud pública [Materias Investigacion]business.industryProportional hazards modelMediterranean RegionIncidence (epidemiology)PreventionIncidenceConfoundingOsteoporosiMiddle AgedSurgeryDietOli d'olivaOli d'oliva -- Ús terapèuticOsteoporosisDietaFemaleOsteoporosi -- PrevencióbusinessBody mass indexFracturesOlive oilOsteoporotic FracturesCohort studyClinical nutrition (Edinburgh, Scotland)
researchProduct

The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four European countries

2021

Eliminació del VHC; Punt d'equilibri; Infecció d'hepatitis C Eliminación del VHC; Punto de equilibrio; Infección de hepatitis C HCV elimination; Break-even; Hepatitis C infection Background and Aims We assessed the clinical and economic impact of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain. Methods An HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015-2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus di…

:Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost Control::Cost Savings [HEALTH CARE]DiseaseHepacivirusmedicine.disease_cause:Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis Viral Human::Hepatitis C [DISEASES]0302 clinical medicineCost of IllnessMedicine:Other subheadings::/therapeutic use [Other subheadings]Economic impact analysisChronicExit strategyevenLiver NeoplasmsHealth services researchhealthInvestment (macroeconomics)Hepatitis C:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS]break‐EnglandItalyHCV elimination030220 oncology & carcinogenesisOriginal Article030211 gastroenterology & hepatologyLiver Disease and Public HealthHumanHepatitis C virusSettore SECS-P/03hepatitis C infectionMedicaments antivírics- Ús terapèuticAntiviral AgentsTime-to-Treatment03 medical and health sciencesbreak-evenHumansbusinessDisease burdenDAAAntiviral Agent:economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::control de costes::ahorro de costes [ATENCIÓN DE SALUD]HepaciviruHepatology:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryRomania:enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis viral humana::hepatitis C [ENFERMEDADES]COVID-19break‐evenDAAsHepatitis C ChronicEstalvi i inversióHcv eliminationCost of IllneSpain:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS]Communicable Disease ControlVirus de l'hepatitis CbusinessDemography
researchProduct

Self-reported antibiotic stewardship and infection control measures from 57 intensive care units: An international ID-IRI survey

2022

Infection control; Multidrug resistance; Stewardship Control de infección; Resistencia a múltiples fármacos; Administración Control d'infecció; Resistència a múltiples fàrmacs; Administració We explored the self-reported antibiotic stewardship (AS), and infection prevention and control (IPC) activities in intensive care units (ICUs) of different income settings. A cross-sectional study was conducted using an online questionnaire to collect data about IPC and AS measures in participating ICUs. The study participants were Infectious Diseases–International Research Initiative (IDI-IR) members, committed as per their institutional agreement form. We analyzed responses from 57 ICUs in 24 countri…

:Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]EpidemiologyIntensive Care UnitInfection controlAmerica:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antibacterianos [COMPUESTOS QUÍMICOS Y DROGAS]Multidrug resistanceCommunicable DiseasesEnquestesPan drug resistanceCommunicable DiseaseAntimicrobial StewardshipSurveys and QuestionnairesAnti-Bacterial AgentHumansMedicaments antibacterians - Ús terapèuticStewardshipSurveys and QuestionnaireSocietyUnitats de cures intensivesCross-Sectional StudieInfection ControlCross InfectionPreventionPublic Health Environmental and Occupational Health:técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]General MedicineMDROAnti-Bacterial AgentsIntensive Care Units:Health Care Facilities Manpower and Services::Health Facilities::Hospital Units::Intensive Care Units [HEALTH CARE]Cross-Sectional StudiesInfectious Diseases:instalaciones servicios y personal de asistencia sanitaria::centros sanitarios::unidades hospitalarias::unidades de cuidados intensivos [ATENCIÓN DE SALUD]:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents [CHEMICALS AND DRUGS]Self ReportMDROsLow- and upper-middle and high incomeHuman
researchProduct

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan : what …

2019

Albuminuria; Atrasentan; Canagliflozin Albuminuria; Atrasentan; Canagliflozina Albuminúria; Atrasentan; Canagliflozina In April 2019, two major Phase 3 randomized clinical trials were published that assessed primary renal outcomes in diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM). The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) tested an already available antidiabetic drug, canagliflozin, and the Study of Diabetic Nephropathy with Atrasentan (SONAR) tested a novel molecule, the endothelin-1 receptor blocker atrasentan, both on top of renin-angiotensin system blockade. Both trials demonstrated significant nephroprot…

:compuestos heterocíclicos::compuestos heterocíclicos de 1 anillo::dioxoles::benzodioxoles::atrasentán [COMPUESTOS QUÍMICOS Y DROGAS]030232 urology & nephrologysodium-glucose cotransporter-2 (SGLT2) inhibitor:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Diabetic nephropathychemistry.chemical_compound0302 clinical medicineChronic kidney diseaseClinical endpointNefropaties diabètiques - Tractament:Other subheadings::/therapeutic use [Other subheadings]canagliflozin:Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores]CanagliflozinSglt2 Inhibitors:enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::nefropatías diabéticas [ENFERMEDADES]Sodium-glucose cotransporter-2 (SGLT2) inhibitorNephrologyendothelinmedicine.drugmedicine.medical_specialty:hidratos de carbono::glicósidos::glucósidos::canagliflozina [COMPUESTOS QUÍMICOS Y DROGAS]UrologyRenal functionalbuminuriaEndothelinNephropathy:Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Nephropathies [DISEASES]03 medical and health sciencesmedicineAlbuminuriaPirrolidina - Ús terapèutic:Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Dioxoles::Benzodioxoles::Atrasentan [CHEMICALS AND DRUGS]CanagliflozinDiabetic kidney diseaseTransplantationCreatinine:Carbohydrates::Glycosides::Glucosides::Canagliflozin [CHEMICALS AND DRUGS]atrasentan:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryAtrasentanGlucòsids - Ús terapèuticmedicine.diseasediabetic kidney diseasechemistryAtrasentanbusinesschronic kidney diseaseKidney disease
researchProduct

Parecer galenico-chymico sobre el antimonio

Títol obtingut de primera pàg Capll

Antimoni Ús terapèutic Obres anteriors al 1800
researchProduct

Effectiveness of substituting cyclosporin A with tacrolimus in reducing gingival overgrowth in renal transplant patients

2009

Objectives: this study aims to evaluate the effectiveness of periodontal therapy combined with tacrolimus in the suppression of gingival overgrowth (GO) and the effect on GO of changing from cyclosporin A to tacrolimus. Patients and methods: sixteen renal transplant patients, averaging 52 years of age, whose kidney function was stable and were receiving treatment with cyclosporin A, were randomly assigned to one of two groups. In the experimental group, patients were instructed in oral hygiene and underwent periodontal treatment, whereas in the control group, only oral hygiene instructions were given. After the first visit and the change of medication from cyclosporine to tacrolimus in both…

ImmunosupressióMalalties de les genivesTrasplantament renalTherapeutic useImmunosupressive agentsMalalties periodontalsTherapeuticsTerapèuticaCiclosperinaGum diseasesKidney transplantationsurgical procedures operativeEfectes secundaris dels medicamentsÚs terapèuticCyclosporineDrug side effectsImmunosupressorsPeriodontal diseaseUNESCO:CIENCIAS MÉDICASImmunosuppression
researchProduct

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

2016

BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in t…

Maleasthma ; serious events ; fluticasone ; salmeterol ; AUSTRIExacerbationIntention to Treat AnalysiINHALED CORTICOSTEROIDSSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled triallawimmune system diseasesÚs terapèuticBroncodilatadors030212 general & internal medicineChildFluticasoneRISKACTING BETA-AGONISTS; INHALED CORTICOSTEROIDS; RISK; EXACERBATIONS; METAANALYSIS; MORTALITY; SAFETY; DEATH; FDAMedicine (all)Hazard ratioDEATHGeneral MedicineBronchodilator agentsMiddle AgedFluticasone-Salmeterol Drug CombinationBronchodilator AgentsIntention to Treat AnalysisAnesthesiaSAFETYFemaleSalmeterolFDAmedicine.drugHumanAdultmedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionate03 medical and health sciencesDouble-Blind MethodInternal medicineAdministration InhalationmedicineHumansMETAANALYSISAsmaBronchodilator AgentAsthmaAgedProportional Hazards ModelsFluticasone-Salmeterol Drug Combinationbusiness.industryMORTALITYACTING BETA-AGONISTSTherapeutic usemedicine.diseaseAsthmarespiratory tract diseasesEXACERBATIONS030228 respiratory systemFluticasone Propionate Salmeterol Xinafoate Drug CombinationProportional Hazards ModelFluticasonebusiness
researchProduct

The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma …

2021

Inhibidor de KIF11; Terapias dirigidas; Metástasis Inhibidor de KIF11; Teràpies dirigides; Metàstasi KIF11 inhibitor; Targeted therapies; Metastasis In summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies. The financial support for this research was provided by Instituto de Salud Calos III (PI20/00530 to Miguel F. Segura; PI20/01107 to Rosa Noguera; PI17/02248 and CPII18/00027 to Anna Santamaria; PI19/013…

Medicine (General)Neuroblastoma - Tractament:neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::tumores neuroectodérmicos primitivos::tumores neuroectodérmicos primitivos periféricos::neuroblastoma [ENFERMEDADES]Metastatic neuroblastomaMedicació oralMedicaments antineoplàstics - Ús terapèutic:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Medicine (miscellaneous)Administration OralKinesinsAntineoplastic Agents:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Letter to Editor:Neoplasms::Neoplasms by Histologic Type::Neoplasms Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms Neuroepithelial::Neuroectodermal Tumors Primitive::Neuroectodermal Tumors Primitive Peripheral::Neuroblastoma [DISEASES]MiceNeuroblastomaR5-920Cell Line Tumor:terapéutica::farmacoterapia::vías de administración de medicamentos::administración oral [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]MedicineAnimalsHumansAntitumor activityPrimary (chemistry)business.industry:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS]Disease Models Animal:Therapeutics::Drug Therapy::Drug Administration Routes::Administration Oral [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Cancer researchMolecular Medicine:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS]businessClinical and Translational Medicine
researchProduct

Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experi…

2022

HCV elimination; Mental health disorders; Sofosbuvir/velpatasvir Eliminación del VHC; Trastornos de salud mental; Sofosbuvir/velpatasvir Eliminació del VHC; Trastorns de salut mental; Sofosbuvir/velpatasvir Hepatitis C virus (HCV) is prevalent in people with mental health disorders, a priority population to diagnose and cure in order to achieve HCV elimination. This integrated analysis pooled data from 20 cohorts in seven countries to evaluate the real-world effectiveness of the pangenotypic direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) in people with mental health disorders. HCV-infected patients diagnosed with mental health disorders who were treated with SOF/VEL for 12 w…

real-worldGenotype:Mental Disorders [PSYCHIATRY AND PSYCHOLOGY]:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Hepacivirus:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Antiviral AgentsMental health disordersVirologyMedicaments antivírics - Ús terapèuticHumans:Other subheadings::/therapeutic use [Other subheadings]sofosbuvir/velpatasvir:trastornos mentales [PSIQUIATRÍA Y PSICOLOGÍA]:Otros calificadores::/uso terapéutico [Otros calificadores]Mental Disorders:virosis::hepatitis viral humana::hepatitis C [ENFERMEDADES]:Virus Diseases::Hepatitis Viral Human::Hepatitis C [DISEASES]HCV elimination; HCV; mental health disorders; real-world; sofosbuvir/velpatasvirHepatitis C:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS]Infectious DiseasesReal-worldSofosbuvir/velpatasvirHCV elimination:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS]HCVmental health disordersSofosbuvirMalalties mentalsHepatitis C - TractamentViruses
researchProduct